News

Establishment and inaugural meeting of the Clinical and Scientific Advisory Board

Accel-Heal are delighted to announce the establishment of a Clinical and Scientific Advisory Board comprised of eminent experts in the fields of Wound Healing research, science, clinical practice, pain management and health economics. The Board is chaired by Dr Robin Martin, PhD, Independent Scientific Consultant and is joined by the following members: Dr Leanne...

‘Electrical stimulation therapy and electroceutical treatment for the management of venous leg ulcers’ published in Community Wound Care

The use of innovative technologies for transforming and improving clinical outcomes and reducing costs in the NHS was an integral component of the NHS Five Year Forward View (2014). The use of electroceutical treatment has been demonstrated to both improve patient outcomes and reduce costs to the NHS for the management of chronic wounds. Read...

‘The health economic burden that acute and chronic wounds impose on an average clinical commissioning group / health board in the UK’ published in the Journal of Wound Care

It is estimated that the annual prevalence of chronic wounds is growing at the rate of 12%; largely as a result of an average healing rate of 43%. At this growth rate, chronic wounds alone (leg, foot and pressure ulcers) are expected to cost £5.3bn per annum by 2017/2018 and £9.4bn a year in another...

‘Health economic burden that different wound types impose on the UK’s National Health Service’ published in the International Wound Journal

Of the £5.3 billion the NHS spend every year treating wounds, over £3.0 billion a year is spent on managing chronic wounds (leg ulcers, diabetic foot ulcers and pressure sores) alone. The majority (74%) of this spend was on wounds that did not heal in the year. Healed wounds cost £800 million while unhealed wounds...

‘Using electroceutical treatment to reduce symptoms and improve healing in chronic wounds’ published in Primary Health Care

Use of electroceutical treatment effectively restores the current of injury, expediting normal healing and reducing chronic inflammation, biofilms, infection and associated symptoms, such as pain and high exudate. Clinical outcomes and QoL are improved and there are also economic benefits. Read the publication here: Using electroceutical treatment to reduce symptoms and improve healing in chronic...

‘Breaking the cycle of hard-to-heal wounds with electroceutical treatment’ presentation to the Leg Ulcers: Right Care, Right Time Wounds UK Nurse Symposium

Liz Ovens, Independent Tissue Viability Nurse and Associate Lecturer, Bucks New University delivered a presentation on the clinical and cost-effectiveness of Accel-Heal® on hard-to-heal wounds. View the poster here: Breaking the cycle of hard-to-heal wounds with electroceutical treatment (pdf) Liz Ovens, Independent Tissue Viability Nurse and Associate Lecturer Bucks New University, Wounds UK Bristol Nurse Symposium,...

‘Venous leg ulcer management in clinical practice in the UK: costs and outcomes’ published in the International Wound Journal

Cost-effective management and healing of VLUs remains a challenging problem for the NHS. The study found that the annual cost of managing an unhealed VLU was £13,500 compared to £3,000 for a healed VLU based on 2015/2016 prices. The number of new VLUs in the UK has been estimated to rise to 170 000 in...

‘Right Care, Right Time – An evaluation using an electroceutical treatment to determine the clinical outcomes in a large NHS Trust’ poster presented at Wounds UK

Significant wound size reduction and healing. Within the 20 week period following treatment, 84% of all wounds healed and 100% of all wounds < 1 year old prior to treatment healed. Using Accel-Heal® can significantly improve clinical outcomes for patients when used alongside standard therapy. Development of a pathway to be incorporated into Trusts’ formularies...

Find your local Accel-Heal Distributor